Implanet Strengthens IP Protection of JAZZ Portfolio Through 2032

IMPLANET, a company specializing in vertebral and knee-surgery implants, has been granted a patent from the U.S. Patent and Trademark Office for the JAZZ technological platform in the United States.
 
The JAZZ technological platform’s intellectual protection now covers the braided implant and its tensioning system, the principal element of its instrumentation. Implanet now possesses intellectual property architecture covering the specificities of its JAZZ platform in the countries defined as priority markets during the company’s initial public offering—the United States, Europe, China, Japan, Australia and South Africa. Implanet is now the only spine surgery player, other than Zimmer Spine, to have patents for a spinal fixation technical solution enabling the braid’s tension and the implant’s position on the rod to be locked with a single screw.

“Being granted this patent in the world’s most advanced medical market represents major recognition by the authorities of the pre-eminence of our spine implant technology. This patent is a guarantee of JAZZ’s future in the United States, where surgeons demand increasingly innovative medical technologies,” said Régis Le Couedic, Implanet’s product development and manufacturing director. “Our band implant and its tensioning instrument are now protected in our priority markets, and we will continue to extend our field of protection to other innovations currently in late-stage development.”
 
“Obtaining this patent is a major value-creation milestone for Implanet. This protection creates a solid barrier to potential competitors in an American market that places a strong emphasis on intellectual property rights. Thanks to this protection, we have total confidence in our continued acceleration in the United States,” Implanet CEO Ludovic Lastennet added.
 
Founded in 2007, IMPLANET manufactures implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the U.S. Food and Drug Administration and the CE mark. IMPLANET employs 48 people and recorded 2015 sales of 6.7 million euros.
 
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston, Mass., in 2013. IMPLANET is listed on Compartment C of the Euronext regulated market in Paris, France.